Dynavax(DVAX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates • HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-overyear growth • Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share • Expect positive net income in 2024, achieving full year profitability • Strengthened cash position to $764 million in Q3'24 • $200 million sha ...